Pneumonia and benign acute myositis of childhood due to Mycoplasma pneu-moniae associated with encephalitis: A case report
Noé Atamari-Anahui,
Yamali Benites-Cóndor,
Maycol Suker Ccorahua-Rios,
Marilyn Carmen Rodríguez-Camino,
Evelina Andrea Rondón-Abuhadba,
Héctor Núñez-Paucar
Affiliations
Noé Atamari-Anahui
Noé Atamari-AnahuiInstituto Nacional de Salud del Niño-Breña, Asociación de Médicos Residentes del Instituto Nacional de Salud del Niño (AMERINSN), Lima, Perú; Universidad San Ignacio de Loyola, Vicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Lima, Perú
Yamali Benites-Cóndor
Instituto Nacional de Salud del Niño-Breña, Asociación de Médicos Residentes del Instituto Nacional de Salud del Niño (AMERINSN), Lima, Perú
Maycol Suker Ccorahua-Rios
Universidad Nacional de San Antonio Abad del Cusco, Facultad de Ciencias de la Salud, Escuela Profesional de Medicina Humana, Cusco, Perú
Marilyn Carmen Rodríguez-Camino
Universidad Nacional de San Antonio Abad del Cusco, Facultad de Ciencias de la Salud, Escuela Profesional de Medicina Humana, Cusco, Perú
Evelina Andrea Rondón-Abuhadba
Universidad Nacional de San Antonio Abad del Cusco, Facultad de Ciencias de la Salud, Escuela Profesional de Medicina Humana, Cusco, Perú
Héctor Núñez-Paucar
Instituto Nacional de Salud del Niño – Breña, Servicio de Neumología, Lima, Perú
One of the leading causes of pneumonia in children between 5 to 15 years is Mycoplasma pneumoniae, a bacterium that causes atypical clinical manifestations such as myositis and encephalitis. We report a 5-year-old girl who presented functional limitations of the lower extremities preceded by an upper respiratory infection. Later on, she developed pneumonia and encephalitis. Antibiotics and antivirals were administered due to the clinical deterioration of the patient. IgM serology for Mycoplasma pneumoniae was positive, while the other viral studies were negative. The clinical course was favorable with a progressive decrease in respiratory distress, sensorial disorder, and improvement in the functional limitations of the lower limbs after 15 days of treatment.